Reliance Clinical Testing Service
Irving, Texas, 75062, United States
NCT Number: NCT02979210
The rationale for the study is to better understand the dynamics of skin microflora following skin barrier disruption in an adult dermatitis model. The results from this study will provide insights in the complex interaction between skin microbiome and epidermis under normal and disease conditions
Looking for future studies?
Notify Me18 year–40 year
Female
Interventional
Not applicable
Irving, Texas, 75062, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
200 microliters of phosphate buffered saline
Time frame: up to 7 days
Microbes will be identified by metagenomic sequencing
Time frame: up to 7 days
Kimberly-Clark Corporation
Industry
Fecal Insult Study: An Exploratory Study to Evaluate the Microbial Consortia and Skin Barrier Function After Exposure to Artificial Fecal Irritants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07637695
Dermatitis, Incontinence-associated Dermatitis
Longtan, Taoyuan City, Taiwan
View Trial DetailsNCT07428954
Acne, Acne Vulgaris
Bilbao, Basque Country, Spain
View Trial DetailsNCT02558738
Dermatitis, Ear Diseases
Elmshorn, Germany
View Trial DetailsNCT01840605
Atopic, Dermatitis
Hokkaido, Japan
View Trial Details